scholarly journals Biomechanical factors related to clinical vs. structural progression of knee OA

2019 ◽  
Vol 27 ◽  
pp. S18
Author(s):  
C.L. Hubley-Kozey
2012 ◽  
Vol 20 ◽  
pp. S76-S77 ◽  
Author(s):  
G.H. Lo ◽  
E. Schneider ◽  
L. Price ◽  
J. Driban ◽  
A. Tassinari ◽  
...  

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 364.2-365
Author(s):  
A.R. Bihlet ◽  
A.-C. Bay-Jensen ◽  
M.A. Karsdal ◽  
I. Byrjalsen ◽  
B.J. Riis ◽  
...  

2015 ◽  
Vol 23 ◽  
pp. A236-A237
Author(s):  
D. Kumar ◽  
C. Wyatt ◽  
N. Okazaki ◽  
K. Chiba ◽  
S. Lee ◽  
...  

2021 ◽  
Vol 10 (15) ◽  
pp. 3353
Author(s):  
Camille Roubille ◽  
Joël Coste ◽  
Jérémie Sellam ◽  
Anne-Christine Rat ◽  
Francis Guillemin ◽  
...  

We aimed to explore the relationship between comorbidities and the structural progression in symptomatic knee and/or hip osteoarthritis (OA) patients. We analyzed the 5-year outcome of non-obese participants (body mass index (BMI) < 30 kg/m2) from the KHOALA cohort having symptomatic hip and/or knee OA (Kellgren and Lawrence (KL) ≥ 2). The primary endpoint was radiological progression, defined as ΔKL ≥ 1 of the target joint at 5 years. The secondary outcome was the incidence of total knee or hip replacement over 5 years. Dichotomous logistic regression models assessed the relationship of comorbidities with KL progression and joint replacement while controlling for gender, age and BMI. Data from 384 non-obese participants were analyzed, 151 with hip OA and 254 with knee OA. At 5 years, cardiovascular diseases (CVD) were significantly associated with the 5-year KL change in both knee (OR = 2.56 (1.14–5.78), p = 0.02) and hip OA (OR = 3.45 (1.06–11.17), p = 0.04). No significant relationship was found between any type of comorbidities and knee or hip arthroplasty. This 5-year association between CVD and radiological progression of knee and hip OA in non-obese participants argue for an integrated management of CVD in knee and hip OA non-obese patients.


Author(s):  
Amjad Waheed Yousuf ◽  
Awhad Mueed Yousuf ◽  
Aasiy Ul Erum

Knee Osteoarthritis (OA) is a major cause of pain and disability worldwide. In majority of cases of knee OA the etiology remains unidentified, however, a number of systemic and local biomechanical factors have been associated with the increased risk of this disorder. These factors may determine the onset of knee OA and rapidity with which the disorder progresses. Occupation and sports participation are among the commonly implicated risk factors and have been studied in detail for their relationship with knee OA. An increased risk of knee OA has been observed in people who are involved in jobs requiring bending and kneeling of the knee joint. Likewise, persons who participate in sports involving excessive strain of the knee joint also carry a higher risk of development of this disorder in the later part of their life. In this review we present the data, obtained from original resources, determining the relationship between occupation and sports participation with the onset and progression of knee OA.


2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 789.2-789
Author(s):  
B. Antony ◽  
Z. Wang ◽  
T. Winzenberg ◽  
G. Cai ◽  
L. Laslett ◽  
...  

Background:Pharmacological therapies are limited, associated with off-target effects, are frequently contraindicated, and only modestly effective for pain in osteoarthritis (OA). Effusion and synovitis are common in OA and are associated with symptomatic and structural progression of OA.Curcuma longa(Turmeric) extract has anti-inflammatory effects and is gaining popularity in the treatment of OA despite the lack of high-quality evidence.Objectives:The CurKOA trial aimed to determine the efficacy ofCurcuma longaextract for reducing knee symptoms and effusion-synovitis in patients with symptomatic knee OA and knee effusion-synovitis.Methods:In this randomised, double-blind, placebo-controlled trial, participants with significant knee pain (≥ 40 mm on a 100-mm visual analog scale [VAS]), symptomatic knee OA (by ACR criteria) and ultrasound defined effusion-synovitis were randomised to receiveCurcuma longaextract (80% aqueous based extract standardized to turmerosaccharides + 20% curcuminoids, 2 × 500 mg capsules/day) or identical placebo for 12 weeks. Knee MRI scans were obtained at baseline and 12 weeks. Coprimary outcomes were changes in knee pain assessed by VAS and change in knee effusion-synovitis volume assessed by MRI over 12 weeks.Results:Among 70 participants (36 receivedCurcuma longa, 34 received placebo, age 61.8±8.6 years, 56% female),Curcuma longasignificantly improved VAS knee pain compared to placebo (-9.11mm, 95% confidence interval [CI] [- 17.79 to -0.44]) over 12 weeks, equivalent to a standardised effect size of 0.50. There was no significant between group difference in change in effusion-synovitis volume (3.24 mL [-0.33, 6.82]). There were significantly greater reductions in WOMAC knee pain (-47.22mm [-81.22, -13.22]), WOMAC function (-112.26mm [-222.79 to -1.74]) and significantly more OARSI-OMERACT treatment responders (63% treatment vs. 38% placebo [Risk Ratio=1.64 (1.00 to 2.70)]) in theCurcuma longagroup compared to the placebo group. There was no significant between-group difference in lateral femoral cartilage T2 relaxation time (-0.38 ms [- 1.10 to 0.34]) assessed from compositional MRI. The incidence of adverse events was similar in theCurcuma longa(n=14 (39%)) and placebo (n=18 (53%)) groups over 12 weeks (P=0.24).Conclusion:An extract ofCurcuma longasignificantly improved knee pain in an inflammatory phenotype of knee OA patients over 12 weeks compared to placebo but had no effect on knee effusion-synovitis and cartilage composition assessed using MRI. The moderate effect size of the treatment supports the use ofCurcuma longaextract for the symptomatic management of knee OA.Figure 1.Change in VAS and WOMAC subscale scores in treatment and control groups over the course of the study. (VAS = Visual analog scale, WOMAC = Western Ontario and McMaster University Index, CL = Curcuma longa extract)Disclosure of Interests:None declared


Rheumatology ◽  
2021 ◽  
Author(s):  
Dong Jin Go ◽  
Dong Hyun Kim ◽  
Jie Young Kim ◽  
Ali Guermazi ◽  
Michel Daoud Crema ◽  
...  

Abstract Objectives Emerging evidence suggests a potential link between OA and gout; however, the association between serum uric acid (UA) itself and knee OA remains uncertain due to a lack of longitudinal studies. Here, we investigated the association between serum UA and knee OA according to cartilage status in elderly community residents without gout. Methods In this longitudinal study, participants without a history of gout were recruited from among the Korean cohort of the Hallym Aging Study (n = 296 for radiography study and n = 223 for MRI study). Weight-bearing knee radiographs and 1.5-T MRI scans, along with blood collection for analysis of serum UA, were performed at baseline and after 3 years. The severity and structural progression of knee OA were evaluated using the Kellgren–Lawrence grading system and the Whole-Organ MRI Score (WORMS) cartilage scoring method. Multivariable logistic regression analysis was conducted using generalized estimating equation (GEE) models. Results Serum UA levels were not associated with radiographic progression after adjusting for age, sex and BMI. There was no significant association between serum UA and tibiofemoral cartilage loss on MRI. However, baseline serum UA levels were negatively associated with patellofemoral cartilage loss over 3 years (adjusted odd ratio 0.70 per 1 mg/dl increase, 95% CI: 0.49, 0.98). Conclusion In this population-based cohort, serum UA was not a risk factor for knee OA progression. Further large-scale longitudinal studies in other populations are needed to validate the effects of UA on cartilage damage.


Sign in / Sign up

Export Citation Format

Share Document